Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.
Cell Res
; 32(4): 404-406, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1655559
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19 Drug Treatment
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Cell Res
Year:
2022
Document Type:
Article
Affiliation country:
S41422-022-00617-X
Similar
MEDLINE
...
LILACS
LIS